Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors
Nicola Fleming, Peter Shane Hamblin, David Story, Elif Ekinci
The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 2020
INTRODUCTION: Sodium glucose cotransporter 2 inhibitors (SGLT2i) have emerged as an important class of blood glucose-lowering medications, due to cardiovascular, metabolic, and renal benefits. However, there is a small but significant risk of diabetic ketoacidosis (DKA) associated with their use. METHODS: A literature search was conducted in Ovid MEDLINE and Embase to July 2019 using variants on the key search terms sodium-glucose cotransporter 2, diabetic ketoacidosis, and type 2 diabetes. A broad spectrum of evidence was incorporated to facilitate a comprehensive narrative review. Further sources were identified through hand searching of reference lists. DISCUSSION: Although cardiovascular..View full abstract
EIE's institution has received research funding from Bayer, Sanofi, Novo Nordisk, Gilead.